Stocks Health care ANAB
NASDAQ · Health careAnaptysbio, Inc (ANAB)
Anaptysbio, Inc brought in $232.4M of revenue over the twelve months to March 31, 2026, up 107.7% from a year earlier. It posted a net loss of $26.8M. Operating cash flow minus capital spending left $19.6M of free cash flow in fiscal 2025. At March 31, 2026 it held $248.5M in cash. Its latest periodic report to the SEC is the transition-period annual report (10-KT) filed on September 21, 2026.
Key facts about Anaptysbio, Inc
- Net worth
- Anaptysbio, Inc has a market value (market cap) of $1.4B at the latest share price, and shareholders' equity of $12.7M on its balance sheet at March 31, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $234.6M (+157.0% year on year), with a net loss of $13.2M. Over the 12 months to March 31, 2026: revenue $232.4M, net loss $26.8M.
- Cash flow
- In fiscal 2025 operations brought in $19.7M of cash; after $87K of capital spending, free cash flow was $19.6M.
- Latest report
- The latest periodic report (transition-period annual report, 10-KT) was filed with the SEC on September 21, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
What Anaptysbio, Inc does
Anaptysbio, Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ANAB.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $234.6M | -$13.2M | -$0.44 | $19.6M |
| 2024 | $91.3M | -$145.2M | -$4.92 | -$135.7M |
| 2023 | $17.2M | -$163.6M | -$6.08 | -$121.6M |
| 2022 | $10.3M | -$128.7M | -$4.57 | -$74M |
| 2021 | $63.2M | -$57.8M | -$2.11 | -$47.3M |
| 2020 | $75M | -$19.9M | -$0.73 | -$14.7M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ANAB ranks in Health care
Latest SEC filings
What Anaptysbio, Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 21, 2026Transition-period annual report 10-KT · period to June 30, 2026
- September 21, 2026Exhibits 8-K
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 11, 2026
- July 30, 2026
- June 29, 2026
- June 29, 2026Additional proxy material DEFA14A
- June 29, 2026Proxy statement DEF 14A
- June 22, 2026
- May 29, 2026
What is ANAB worth? A DCF from its reported cash flow
Insider trades
What the people running Anaptysbio, Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $249.4K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 1, 2026 | Renton HollingsDirector | Exercised options | 5,000 | $90.2K |
| October 1, 2026 | Renton HollingsDirector | Soldpre-planned (10b5-1) | 5,000 | $249.4K |
| September 15, 2026 | Orwin John ADirector | Exercised options | 1,300 | - |
| June 15, 2026 | Renton HollingsDirector | Exercised options | 6,030 | - |
| June 15, 2026 | Orwin John ADirector | Exercised options | 6,030 | - |
| June 15, 2026 | Schmid John P.Director | Exercised options | 6,030 | - |
| March 30, 2026 | Schmid John P.Director | Sold | 12,596 | $701.7K |
| March 30, 2026 | Schmid John P.Director | Sold | 7,527 | $426.8K |
Who owns ANAB
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| EcoR1 Capital, LLC13D, may seek influence with 2 related filers | 25.8% | August 16, 2024 |
| Sirenia Capital Management LP13G, passive with 1 related filers | 5% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 213 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| EcoR1 Capital, LLC | 7,880,094 | 0 |
| BlackRock, Inc. | 1,844,049 | +162,669 |
| Tang Capital Management LLC | 1,330,879 | 0 |
| State Street Corp | 1,286,194 | +293,749 |
| Vanguard Capital Management LLC | 906,233 | +53,082 |
| Affinity Asset Advisors, LLC | 826,109 | -113,891 |
| Sanofi | 821,917 | 0 |
| Millennium Management LLC | 807,316 | +331,744 |
| Woodline Partners LP | 717,014 | +372,758 |
| 683 Capital Management, LLC | 660,000 | +35,000 |
| Geode Capital Management, LLC | 637,873 | +117,632 |
| Palo Alto Investors LP | 603,489 | -34,672 |
| Goldman Sachs Group Inc | 584,070 | +251,327 |
| First Light Asset Management, LLC | 582,004 | +16,573 |
| D. E. Shaw & Co., Inc. | 539,666 | -39,630 |
| Vanguard Portfolio Management LLC | 527,858 | +7,988 |
| Apis Capital Advisors, LLC | 497,000 | +259,000 |
| Sofinnova Investments, Inc. | 493,536 | +245,283 |
| Arrowstreet Capital, Limited Partnership | 488,651 | -3,469 |
| Nuveen, LLC | 420,664 | +104,599 |
Insiders
9 insiders reported holding 658,942 shares in total, about $31.6M at the last price.
| Holder | Shares |
|---|---|
| Faga DanielPresident, CEO, Director | 495,965 |
| Lizzul Paul F.Chief Medical Officer | 42,088 |
| Schmid John P.Director | 37,652 |
| Mulroy DennisCHIEF FINANCIAL OFFICER | 21,852 |
| Orwin John ADirector | 17,995 |
| Loumeau Eric JCHIEF LEGAL OFFICER | 12,835 |
| Renton HollingsDirector | 10,995 |
| Marquet MagdaDirector | 9,930 |
| Ware J. AnthonyDirector | 9,630 |
Questions about ANAB
What does Anaptysbio, Inc do?
Anaptysbio, Inc is a company in the Health care sector, listed on NASDAQ as ANAB. Its shares trade on NASDAQ under the ticker ANAB.
What is Anaptysbio, Inc's net worth?
Anaptysbio, Inc has a market value (market cap) of $1.4B at the latest share price, and shareholders' equity of $12.7M on its balance sheet at March 31, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Anaptysbio, Inc profitable?
No. Over the twelve months to March 31, 2026 it reported a net loss of $26.8M on revenue of $232.4M.
How much revenue does Anaptysbio, Inc make?
Over the twelve months to March 31, 2026 Anaptysbio, Inc reported revenue of $232.4M. That is 107.7% more than a year earlier.
When did Anaptysbio, Inc last report?
Its most recent periodic report is the transition-period annual report (10-KT) filed on September 21, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from October 2, 2026.
Similar companies
Compare ANAB with
Follow ANAB
Get an email when Anaptysbio, Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Anaptysbio, Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.